×
ADVERTISEMENT

DECEMBER 16, 2024

FDA Approves Unloxcyt for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma


Originally published by our sister publication Clinical Oncology News

By Clinical Oncology News Staff

The FDA approved cosibelimab-ipdl (Unloxcyt, Checkpoint Therapeutics), a programmed death ligand-1 (PD-L1) blocking antibody, for adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation.

Efficacy was evaluated in Study CK-301-101 (ClinicalTrials.gov. Identifier: NCT03212404), a multicenter,